Your browser doesn't support javascript.
loading
Immunogenicity, Safety, and Efficacy of Influenza Vaccine in T2DM and T2DM with Chronic Kidney Disease.
Heryaman, Henhen; Juli, Cep; Nazir, Arnengsih; Syamsunarno, Mas Rizky A A; Yahaya, Badrul Hisham; Turbawaty, Dewi Kartika; Sari, Rini Mulia; Permana, Hikmat; Supriyadi, Rudi; Atik, Nur.
Affiliation
  • Heryaman H; Doctoral Program, Faculty of Medicine, Padjadjaran University, Bandung 40161, Indonesia.
  • Juli C; Department of Biomedical Sciences, Faculty of Medicine, Padjadjaran University, Bandung 45363, Indonesia.
  • Nazir A; Department of Neurology, Dr. Hasan Sadikin General Hospital, Faculty of Medicine, Padjadjaran University, Bandung 40161, Indonesia.
  • Syamsunarno MRAA; Doctoral Program, Faculty of Medicine, Padjadjaran University, Bandung 40161, Indonesia.
  • Yahaya BH; Department of Biomedical Sciences, Faculty of Medicine, Padjadjaran University, Bandung 45363, Indonesia.
  • Turbawaty DK; Department of Biomedical Sciences, Advanced Medical and Dental Institute (IPPT), Universiti Sains Malaysia, Bertam Kepala Batas 13200, Malaysia.
  • Sari RM; Departemen of Clinical Pathology, Dr. Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.
  • Permana H; PT Biofarma, Bandung 40161, Indonesia.
  • Supriyadi R; Division of Endocrinology and Metabolism, Internal Medicine Department, Dr. Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.
  • Atik N; Division of Nephrology, Internal Medicine Department, Dr. Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.
Vaccines (Basel) ; 12(3)2024 Feb 23.
Article de En | MEDLINE | ID: mdl-38543861
ABSTRACT
Patients with Type 2 diabetes mellitus (T2DM) and Chronic Kidney Disease (CKD) face an increased risk of morbidity and mortality after influenza infection. Several studies have shown that the influenza vaccine effectively prevents morbidity and mortality in T2DM patients. However, there has been limited research aimed at assessing the effectiveness of the trivalent influenza vaccine in T2DM-CKD patients. This study aimed to identify Geometric Mean Titers (GMTs), seroprotection, seroconversion, safety, and efficacy. This open-label clinical trial was conducted at AMC Hospital in Bandung, West Java, Indonesia between June 2021 and July 2022. The study subjects consisted of 41 T2DM and 26 T2DM-CKD patients who were administered the trivalent influenza vaccine. There was a significant difference in the average age, with the T2DM-CKD patients being older. Median titers post-vaccination for the B/Washington virus were higher in the T2DM patients compared to the T2DM-CKD patients, and this difference was statistically significant. A majority, comprising 75.6% of the T2DM and 80.8% of the T2DM-CKD patients monitored post-influenza-vaccination, did not experience any adverse reactions. The most common reaction was the sensation of fever, with incidence rates of 12.2% in the T2DM patients and 15.4% in the T2DM-CKD patients. Furthermore, we observed that the incidence of Influenza-like Illness was highest at 7.3% in the T2DM patients and 7.7% in the T2DM-CKD patients. The trivalent influenza vaccine demonstrated equivalent safety and effectiveness in both groups.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Vaccines (Basel) Année: 2024 Type de document: Article Pays d'affiliation: Indonésie Pays de publication: Suisse

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Vaccines (Basel) Année: 2024 Type de document: Article Pays d'affiliation: Indonésie Pays de publication: Suisse